September 12, 2014
Going Anti-Access at Sea: How Japan Can Turn the Tables on China
The CNAS Asia-Pacific Security Program’s Maritime Strategy Series aims to explore various types and facets of strategies to deter, deny and impose costs on provocative behavior in maritime Asia, as part of an overall effort to preserve that region’s long-term peace and stability. In this second paper in the Maritime Strategy Series, Professor Toshi Yoshihara of the U.S. Naval War College examines how Tokyo can, in the context of a consistently defensive approach to security and a strong U.S.-Japan alliance, adopt asymmetric strategies to counter negative trends in relative maritime power between Japan and China. He concludes that Japan could leverage existing capabilities, human and physical capital to better deny war aims of potential aggressors, thus bolstering defense and deterrence, strengthening the alliance with Washington, and contributing to the overall peace of maritime East Asia.
Author
-
Toshi Yoshihara
More from CNAS
-
Podcast
Defense / Indo-Pacific Security
Hellscape Taiwan: Drones, Deterrence, and the Future of Asymmetric DefenseStacie Pettyjohn joined the Irregular Warfare Podcast to examine how Taiwan could deter—or potentially defeat—a Chinese invasion by transforming the Taiwan Strait into an “unm...
By Stacie Pettyjohn
-
Video
Indo-Pacific Security / Energy, Economics & Security
Analysts Break Down Trump-Xi Meeting and Calls for Stability and CooperationFor perspective on President Trump's trip and the broader U.S.-China relationship, Geoff Bennett spoke with Myron Brilliant and Liza Tobin. Brilliant is at the DGA Group and i...
By Liza Tobin
-
Video
Indo-Pacific Security / Energy, Economics & Security
Rajdeep Sardesai Asks Big Question on US-ChinaThe debate on the Big Question, with Daniel Silverberg, adjunct senior fellow at the Center for a New American Security, explores whether Beijing holds the key to resolving th...
By Daniel Silverberg
-
China’s Pharmaceutical Weapon
Commentary
Until SAPIR is extended to biologically derived drugs, until the FDA clears the bovine pathway, and until at least one American-owned heparin manufacturer operates on US soil,...
By Jennifer Hendrixson White
